[{"id":"e8653406-69af-4f9e-9ba7-c10bb02ed4cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04053673","created_at":"2021-01-18T19:52:32.992Z","updated_at":"2024-07-02T16:35:52.181Z","phase":"Phase 1","brief_title":"Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors","source_id_and_acronym":"NCT04053673","lead_sponsor":"Ribon Therapeutics, Inc.","biomarkers":" HER-2 • ER • PGR • TIPARP","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • TIPARP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atamparib (RBN-2397)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2023-03-28"}]